A) CYP2C9

B) VKORC1

C) CYP4F2

D) CYP2C19

Fig. 3. Genotype variants and warfarin dose. Numbers in parenthesis represent the number of patients. Data are expressed as means ± SD.

As for the reason why the female patients and those with congestive heart failure had the lower TTR, one possibility is that PT-INR had been kept at relatively low values due to concern about the bleeding events in these patients. We, therefore, evaluated the relationship between these factors and HAS-BLED score [18]. Though we found that, compared without congestive heart failure patients, HAS-BLED score in the patients with congestive heart failure patients were significantly higher (1.66 ± 0.9 vs 2.8 ± 1.2 respectively, p < 0.01) but there was no significant relationship between female gender and HAS-BLED score. The reason why congestive heart failure had negative correlation with TTR is not clear but previous report from RE-LY trial was consistent with our results, though they did not also find proper explanation for this. We tried to analyze the relationship between TTR and HAS-BLED score because we considered that Japanese physicians might have intentionally administered warfarin so as to attain the lower PT-INR value than what is recommended in the guideline due to an anxiety against the hemorrhage accident. HAS-BLED score consists of hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, elderly, drugs/alcohol concomitantly and labile INR. However, it is obvious that labile INR defined as <60% of TTR is inappropriate to be included in the analysis. Also hypertension, abnormal renal function, stroke, elderly, and drugs concomitantly had already existed in our original calculation as analysing factors. Thus we adopted only abnormal liver function, bleeding history or predisposition, and alcohol concomitantly as independent candidates which affect TTR. As for alcohol, since only one patient had taken alcohol regularly, we considered that to include this factor has no mean and abandoned to include in this analysis. Thus, we analysed the relationship between TTR and two components of HAS-BLED score; abnormal liver function, bleeding history or predisposition. Though thirteen patients have abnormal liver function and 6 patients had bleeding history, these components were not significantly associated with TTR (p = 0.82 in abnormal liver function, p = 0.55 in bleeding history or predisposition).

Study Limitations

As we retrospectively analyzed the records of NVAF patients who were taking warfarin and who could come to each hospital on foot,

this study might have excluded some immobile patients as the result of a major stroke or hemorrhage due to poor control of PT-INR, i.e. very low TTR. In another words, there remains a possibility that our average of TTR might have been skewed toward better side. To overcome this shortcoming, a larger prospective study is needed.

Though we found that the most participated cardiologist in our study controlled using 1.6-2.6 of PT-INR range irrespective of age and this tendency was confirmed by a recent Japanese large cohort, we have no data about the outcome of this lower control. Whether our analysis has clinical meaning partially or not depends on the outcome using this control range. We have to pay attention to the result of the cohort study.

Clinical Implications

As we found that female gender, and presence of congestive heart failure were associated to the lower TTR control, more attention should be paid to such high risk patients in daily practice.

Conflict of Interest Statement

All authors declare no conflicts of interest.

Role of the Funding Sources

Acknowledgement

References

[1] Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol 2007;6:981–93.

[2] Hart RG, Pearce LA, Aguilar MI. Meta-analysis. Antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007;146:857–67.

[3] Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029–37.

[4] Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37–41.

[5] Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. - A multicenter study of its status and influential factors-. Circ J 2011;75:2087–94.

[6] Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 2006;51:249–53.

[7] The International Warfarin Pharmacogenetics Consortium. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. N Engl J Med 2009;360:753–64.

[8] Aomori T, Yamamoto K, Oguchi-Katayama A, Kawai Y, Ishidao T, Mitani Y, et al. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2. Clin Chem 2009;55:804–12.

[9] Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633–8.

[10] Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540–6.

[11] Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001;40:1183–8.

[12] JCS Joint Working Group. Guideline for pharmacotherapy of atrial fibrillation (JCS 2008). Circ J 2010;74:2479–500.

[13] Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J 2011;75:1328–33.

[14] Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA 2001;285:2864–70.

[15] Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236–9.

[16] Kotani A, Atarashi H, Inoue H, Okumura K, Yamashita T. Optimal PT-INR for Japanese patients with non-valvular atrial fibrillation under warfarin therapy. -from J-RHYTHM Registry Investigators- Jpn. J Electrocardiol 2012;32(Suppl.-5):72.

[17] Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, et al. Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2012;126:2309–16.

[18] Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173–80.

ORIGINAL ARTICLE

Heart Failure

Prognostic Impact of Blood Urea Nitrogen Changes During Hospitalization in Patients With Acute Heart Failure Syndrome

Masanobu Miura, MD, PhD; Yasuhiko Sakata, MD, PhD; Kotaro Nochioka, MD, PhD;
Jun Takahashi, MD, PhD; Tsuyoshi Takada, MD; Satoshi Miyata, PhD;
Tetsuya Hiramoto, MD, PhD; Kan-ichi Inoue, MD, PhD; Kenji Tamaki, MD, PhD;
Nobuyuki Shiba, MD, PhD; Hiroaki Shimokawa, MD, PhD

Background: Elevated blood urea nitrogen (BUN) observed in patients hospitalized for acute heart failure syndrome (AHFS) may represent increased neurohumoral activation. The purpose of this study was to examine the prognostic impact of BUN changes during hospitalization on the long-term prognosis of AHFS patients.

Methods and Results: The Tohoku Acute Heart Failure Registry (n=497) is a multicenter retrospective cohort study enrolling AHFS patients who were admitted in 2007. The 337 survivors (mean age, 76 years; 52% male) were divided into 3 groups according to tertiles of BUN change during hospitalization: Decreased (D-BUN, ΔBUN (BUN level at discharge–BUN level at hospitalization) ≤−1.63 mg/dl, n=112); Unchanged (U-BUN, ΔBUN −1.64 to 5.73 mg/dl, n=113); Increased (I-BUN, ΔBUN >5.73 mg/dl, n=112). The D-BUN group had higher prevalence of lowest glomerular filtration rate during hospitalization, whereas the I-BUN group had higher systolic blood pressure. During a median follow-up period of 2.3 years after discharge, the Kaplan-Meier curve showed that D-BUN and I-BUN had worse prognosis compared with U-BUN. Multivariable logistic model showed that all-cause death was more frequent in I-BUN (hazard ratio, 2.94; 95% confidence interval, 1.51–5.73; P<0.001). Subgroup analysis revealed that BUN increase during hospitalization was associated with all-cause death, regardless of renal function.

Conclusions: AHFS patients with a BUN increase during hospitalization have worse long-term prognosis, independent of renal function.   (Circ J 2013; 77: 1221–1228)

Key Words: Acute heart failure syndrome; Blood urea nitrogen; Neurohumoral activation; Renal dysfunction

T he activation of neurohumoral factors, including the sympathetic nervous system (SNS), renin-angiotensin-aldosterone system (RAS) and arginine vasopressin (AVP), is considered as the central pathophysiology of heart failure (HF).[1] The elevated SNS and RAS activities in the kidney enhance urea absorption in the proximal tubules and flow-dependent urea absorption in the distal tubules.[1] Furthermore, increased AVP upregulates urea transporters in the inner medullary collecting duct.[1] Thus, an elevated blood urea nitrogen (BUN) level could be regarded as a surrogate marker for neurohumoral activation in HF patients.

Several studies have reported that elevated BUN levels are associated with adverse outcomes in HF patients, especially in those hospitalized because of acute HF syndrome (AHFS).[2–8] Using recursive partitioning of 33,046 AHFS patients with 39 variables, Fonarow et al revealed that the best single predictor for in-hospital death of AHFS patients at admission was high BUN level (≥43 mg/dl), followed by low systolic blood pressure (SBP, <115 mmHg) and high serum creatinine level (≥2.75 mg/dl).[2] In addition, it has been shown that elevated BUN level at admission can predict poor in-hospital and long-term outcomes after the onset of AHFS.[4–8] Accordingly, the BUN level at admission appears to be a useful predictor of survival of AHFS patients.

However, it is unclear whether BUN levels can predict the long-term outcomes of AHFS patients, especially after dis-

charge. In the present study, we thus examined the prognostic implication of BUN level on long-term outcome after discharge in AHFS patients. We particularly focused on the effect of BUN changes during AHFS hospitalization, because evaluation of dynamic changes in the BUN level during hospitalization could be more informative as compared with one-point assessment at admission or discharge.

Methods

The present study was approved by the Ethical Committees of Tohoku University (No. 2009-366) and the other 3 collaborating hospitals. The Ethical Committees judged that informed consent from each patient was not required for the present study.

AHFS Patients and Inclusion Criteria
The Tohoku Acute Heart Failure Registry (n=497) is a multicenter retrospective cohort study, enrolling AHFS patients who were admitted to the 4 participating hospitals. We included consecutive AHFS patients aged ≥20 years who were admitted to the hospitals in 2007. We excluded AHFS patients with acute coronary syndrome, primary pulmonary arterial hypertension or pericardial disease. AHFS was defined as a gradual or rapid change in the signs and symptoms of HF that necessitated urgent hospitalization, diagnosed by experienced cardiologists, based on the criteria of the Framingham Heart Study.[9] Medical records were reviewed by trained clinical research coordinators and the patients' data were collected for the present registry using a pre-fixed registration form. The baseline data included demographic information, medical history, clinical signs and symptoms of HF, and initial treatment at admission. Clinical signs and treatments were surveyed at 24–72h after hospitalization and at discharge. The primary outcome of the present study was all-cause mortality after discharge. Data acquisition was performed from November 2009 to February 2011. Finally, 497 AHFS patients from the 4 participating hospitals were registered.

In the present analysis, we excluded some patients for the following reasons: hospitalization for myocarditis (n=1) or takotsubo cardiomyopathy (n=3); requiring hemodialysis (n=5); insufficient data (n=58). Furthermore, we excluded the patients who did not receive intravenous diuretics (n=43), because intravenous diuretics strongly influence fluid volume status, which may be associated with BUN change during AHFS hospitalization. Additionally, we excluded patients who died during hospitalization (n=50). In total, 337 AHFS survivors were included in the present study. The outcome of the present study was all-cause death. To evaluate the prognostic impact of BUN changes during hospitalization in AHFS patients, we divided the subjects into 3 groups based on the tertile of BUN change during hospitalization: 112 patients whose BUN levels decreased (ΔBUN ≤–1.63, D-BUN group); 113 whose BUN levels were unchanged (ΔBUN, –1.64 to 5.73, U-BUN group); 112 whose BUN levels increased during hospitalization (ΔBUN >5.73, I-BUN group). ΔBUN was defined as BUN level at discharge–BUN level at admission.

BUN Level
BUN level was measured in each participating hospital on admission, at 24–72h after hospitalization and at discharge.

Renal Function
Estimated glomerular filtration rate (eGFR, ml·min^{-1}·1.73m^{-2}) was calculated at the time of hospitalization using the modi-

fied Modification of Diet in Renal Disease equation with the Japanese coefficient.[10] Worsening renal function (WRF) was defined as an increase in serum creatinine at discharge of >0.3mg/dl compared with that at admission, based on previous reports.[11–14]

Statistical Analysis
Comparisons among the 3 groups were performed by ANOVA test. Continuous data are described as mean±standard deviation (SD). Kaplan-Meier curves were plotted to evaluate the association between the BUN changes during hospitalization and all-cause death.

We constructed unadjusted (model a) and adjusted (models b and c) logistic regression models to evaluate the association between BUN changes and outcome. In model (b), we included the following covariates at admission that could influence both the outcome and the BUN changes during hospitalization: age, sex, history of HF hospitalization, SBP, heart rate (HR), hemoglobin level, serum sodium (Na), serum potassium (K), eGFR, comorbidities (diabetes mellitus, history of coronary artery disease (CAD), malignant tumor and cerebrovascular disease), left ventricular ejection fraction (LVEF) and use of inotropes. In model (c), we included the following covariates that could influence BUN changes and prognosis during hospitalization: age, sex, diabetes mellitus, histories of CAD, cerebrovascular disease, and malignant tumor, LVEF, changes in SBP (ΔSBP), HR (ΔHR), serum sodium (ΔNa), serum potassium (ΔK), serum creatinine (ΔCre) and hemoglobin (ΔHb), medical treatment (β-blockers, RAS inhibitors, loop diuretics and aldosterone antagonists) and number of days spent fasting after hospitalization.

We also performed multivariable logistic analysis to compare the prognostic effect of one-point BUN or creatinine level at admission or at discharge, and the change in BUN levels during hospitalization (ΔBUN) and WRF. We adjusted the baseline characteristics that included in model (b). Furthermore, we performed the multivariable logistic regression analysis to determine the predictors of BUN increase during hospitalization in the I-BUN group. We included the following covariates at admission that potentially influence BUN increases during hospitalization: age, sex, New York Heart Association class, history of HF hospitalization, clinical scenario (CS) status, HR, eGFR, diabetes mellitus, histories of CAD, malignant tumor and cerebrovascular disease, LVEF and previous treatment (β-blockers, RAS inhibitors, diuretics, and spironolactone). To examine whether renal function influences the prognostic impact of BUN changes during hospitalization, we examined the influence of BUN and creatinine levels at admission and WRF during hospitalization on BUN changes during hospitalization.

Numerical data are expressed as mean±SD. All statistical analyses were performed using SPSS Statistics 19.0 (SPSS Inc, Chicago, IL, USA) and statistical significance was defined as a 2-sided P-value <0.05.

Results

Baseline Characteristics of AHFS Patients
Mean age was 76.0±12.0 years and male patients accounted for 51.9%. The prevalence of de novo AHFS and Nohria profile C were 70.6% and 19.6%, respectively. CAD was observed in 27.9% and mean LVEF and eGFR at admission were 45.5±16.2% and 46.2±25.8ml·min^{-1}·1.73m^{-2}, respectively. The mean period of hospitalization was 30.4±19.4 days. Carperitide was given to 89% of the study patients after admis-

Table 1. Baseline Characteristics of the Study Patients

Groups	D-BUN	U-BUN	I-BUN	P value
ΔBUN (mg/dl) (median, 95% CI)	−7.8 (−13.8 to −9.5)	1.8 (1.4 to 2.2)	15.5 (13.4 to 17.6)	
n	112	113	112	
Age (years)	76.7±11.9	73.7±13	77.6±10.6	0.04
Male (%)	58	51.3	46.4	0.22
History of HF hospitalization (%)	30.4	24.8	33	0.38
History of malignant tumor (%)	17	13.3	14.3	0.72
Ischemic HF (%)	28.3	28.6	26.8	0.28
Comorbidities (%)				
Hypertension	69.6	70.8	67.9	0.89
Diabetes	43.8	36.3	33	0.24
Atrial fibrillation	50	61.9	50	0.19
Cerebrovascular disease	22.3	18.6	21.4	0.77
Clinical status at admission				
NYHA class III and IV (%)	99.1	93.8	98.3	0.09
Nohria profile C (%)	33.9	12.4	12.5	<0.001
Clinical scenario 1 (%)	52.7	49.6	62.5	0.13
SBP (mmHg)	142.4±36.4	146.2±33.9	153.3±37	0.07
DBP (mmHg)	81.3±26.1	84.3±21.8	86.1±22	0.3
HR (beats/min)	94.2±27.9	101.2±15.8	70.7±13.8	0.17
Clinical variables at admission				
LVEF (%)	45.6±16	45.2±16.5	45.9±16.2	0.96
Hemoglobin (g/dl)	11.6±2.5	12.4±2.2	11.4±2.2	0.006
BUN (mg/dl)	34.8±17.4	21.1±10.6	24.4±12.9	<0.001
Serum Cre (mg/dl)	1.4±0.9	1±0.6	1.2±0.8	0.001
Serum sodium (mEq/L)	139.5±4.4	141±3.9	140.8±4	0.02
Serum potassium (mEq/L)	4.4±0.4	4.2±0.5	4.1±0.7	<0.001
eGFR (ml·min^{-1}·1.73m^{-2})	38.8±18.9	53.6±27.1	46.3±28.4	<0.001
BNP (pg/ml)	1,360±1,662	939±709	1,177±1,167	0.06
Treatment at admission (%)				
Diuretics	58	50.4	54.5	0.52
Carperitide	88	90.9	90.8	0.81
Nitrates	18.8	17.7	17.9	0.98
Dopamine	8.9	8	1.8	0.06
Dobutamine	14.3	8	3.6	0.02
PDE III inhibitor	10.7	5.3	12.5	0.16
Calcium-channel blocker	9.8	9.7	9.8	1
Fasting period (days)	1.9±1.9	1.4±0.7	1.6±0.9	0.02
Length of hospital stay (days)	32.5±20.3	29±20.6	29.6±17.5	0.36

Numerical data are expressed as mean±SD.
D, decreased; BUN, blood urea nitrogen; U, unchanged; I, increased; CI, confidence interval; HF, heart failure; NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; LVEF, left ventricular ejection fraction; Cre, creatinine; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide; PDE, phosphodiesterase.

sion. Furthermore, intravenous furosemide and intensive respiratory management were given to 54.3% and 10.1% of the study patients, respectively.

The mean BUN levels (mg/dl) at admission and discharge were 26.7±15.1 and 28.6±16.2, respectively. We divided the study subjects into 3 groups based on the tertile of the ΔBUN values as mentioned earlier (**Table 1**). The BUN levels at 24–72h after admission was not significantly increased as compared with those at admission in all groups (**Figure 1A**). The U-BUN group was characterized by younger age and had the highest eGFR and lowest brain natriuretic peptide (BNP) level. The D-BUN group was characterized by higher prevalence of Nohria profile C, the highest BNP level and the low-

est eGFR at admission. Furthermore, patients in the D-BUN group were more frequently treated with inotropes (dopamine or dobutamine) at admission. In contrast, the I-BUN group was characterized by older age and had higher SBP at admission and lower hemoglobin level. The fasting period was longer in the I-BUN group than in the U-BUN group (**Table 1**).

Changes in Clinical Variables During Hospitalization

The changes in BUN level and other clinical variables during hospitalization in each group are shown in **Table 2** and **Figure 1**. The mean interval of BUN measurements was 25.7± 23.6 days and was comparable among the 3 groups (21.9±18.8, 27.4±19.8 and 27.8±30.4 days in the U-BUN, D-BUN and

Figure 1. (**A**) Changes in BUN levels during hospitalization for AHFS. (**B**) Changes in creatinine level during hospitalization. (**C**) Changes in BUN/creatinine ratio during hospitalization. AHFS, acute heart failure syndrome; BUN, blood urea nitrogen.

Table 2. Changes in Clinical Variables During Hospitalization and Medications at Discharge

	D-BUN (n=112)	U-BUN (n=113)	I-BUN (n=112)	P value
Changes in clinical variables during hospitalization				
Interval of measurement (days)	27.4±19.7	21.9±18.8	27.8±30.3	0.11
ΔSBP (mmHg)	−26±31.7	−32.7±29.8	−36.8±31.9	0.04
ΔHR (beats/min)	−24.9±28.7	−32.5±31.6	−29.6±27.5	0.16
ΔBUN (mg/dl)	−11.7±11.5	1.8±2	15.5±11.3	<0.001
25% increase in BUN (%)	0	13.3	94.6	<0.001
ΔCre (mg/dl)	−0.2±0.7	0.1±0.2	0.3±0.4	<0.001
0.3mg/dl increase in Cre (%)	5.4	9.7	32.1	<0.001
ΔSerum sodium (mEq/L)	0.7±5.1	−0.6±4.2	−1.2±4.9	0.01
ΔSerum potassium (mEq/L)	−0.1±0.8	0.3±0.6	0.4±0.8	<0.001
ΔHemoglobin (g/dl)	0±1.6	0±1.5	−0.3±1.5	0.27
Oral medications at admission				
Diuretics (%)	58	47.8	50	0.27
Spironolactone (%)	22.3	14.2	21.4	0.23
ACEIs (%)	24.1	22.1	29.5	0.42
ARBs (%)	25.9	25.7	26.8	0.98
β-blockers (%)	21.4	31.9	20.5	0.09
Oral medications at discharge				
Diuretics (%)	85.7	82.3	90.2	0.23
Furosemide dose (mg/day)	35.2±21.1	32.5±17.0	33.7±17.6	0.68
Spironolactone (%)	39.3	40.7	51.8	0.12
ACEIs (%)	50.9	61.1	58.9	0.27
ARBs (%)	31.3	22.1	32.1	0.18
β-blockers (%)	50.9	62.8	50.9	0.12

Numerical data are expressed as mean±SD.
ΔSBP, SBP at discharge–SBP at hospitalization; ΔHR, HR at discharge–HR at hospitalization; ΔBUN, BUN at discharge–BUN at hospitalization; ΔCre, Cre at hospitalization–Cre at discharge; Δserum sodium (Na), Na at discharge–Na at hospitalization; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker. Other abbreviations as in Table 1.

I-BUN groups, respectively, P=0.11, **Figure 1A**). In the I-BUN group, ≥25% increase in BUN level was noted in 94.6% and WRF in 32.1% of the patients (**Figure 1B**). Furthermore, the I-BUN group had the largest BUN/creatinine ratio at discharge among the 3 groups (**Figure 1C**). In the U-BUN group,

≥25% increase in BUN was noted only in 13.3% and the prevalence of WRF was lower than in the I-BUN group. In the I-BUN group, the changes in SBP, serum Na level and serum K level were the largest among the 3 groups.

Medications at Discharge

Among the 3 groups, there was no significant difference in medications at either admission or discharge, although the I-BUN group tended to have more diuretics and spironolactone and the U-BUN group more angiotensin-converting enzyme inhibitors and β-blockers (Table 2). There was no difference in the furosemide dose at discharge among the 3 groups.

Prognostic Impact of BUN Changes During Hospitalization of AHFS Patients

During the median follow-up period of 2.3 years after discharge, 120 patients (35.6%) died. Figure 2 shows the Kaplan-Meier survival curves for all-cause death. The D-BUN and I-BUN groups had worse prognosis compared with the U-BUN group. Furthermore, 3-year mortality rate of the I-BUN group was approximately 150% higher compared with the D-BUN group.

Table 3 shows the results of multivariable logistic regression models for all-cause death. In the unadjusted model (a), as compared with the U-BUN group (reference), both the D-BUN and I-BUN groups showed 181% and 277% increase, respectively, in the risk for all-cause death (P=0.049 and P<0.001, respectively). In model (b), as compared with the U-BUN group (reference), the hazard ratio (95% confidence interval [CI]) for all-cause death of the D-BUN and I-BUN groups was 1.09 (0.54–2.21) and 2.94 (1.51–5.73), respectively. In model (c), the hazard ratio (95% CI) for all-cause death in groups D-BUN and I-BUN was 0.93 (0.43–2.01) and 4.27 (2.14–8.52), respectively, as compared with the U-BUN group (reference). Furthermore, the I-BUN group also had significantly higher hazard ratios for all-cause death as compared with the D-BUN group in both model (b) and (c) (hazard ratio 2.78, 95% CI 1.36–5.68, P=0.002; hazard ratio 4.19, 1.77–9.91, P=0.001, respectively).

Figure 3A shows the results of multivariable logistic models to compare the prognostic impact of BUN and creatinine levels at admission, BUN and creatinine levels at discharge, and BUN increase and WRF during hospitalization for all-cause death. BUN increase during hospitalization had the highest heart rate for all-cause death compared with BUN and creatinine levels both at admission and at discharge. Figure 3B shows that BUN increase was significantly associated with

Figure 2. Kaplan-Meier survival curves for all-cause death.

all-cause death, regardless of serum BUN or creatinine level at admission. Furthermore, the prognostic impact of BUN increase during hospitalization for all-cause death was insignificant in AHFS patients with WRF, whereas it was significant in those without WRF.

Predictors of BUN Increase During Hospitalization

In the I-BUN group, the prevalence of patients with ≥25% increase in BUN level during hospitalization was 94.6%. Among the covariates, only SBP at admission was associated with the increase in BUN level during hospitalization (Table 4). The analysis also showed that CS1 (SBP >140 mmHg) was associated with 81% increase in the prevalence of the BUN increase compared with CS >1 (hazard ratio 1.81, 95% CI 1.05–3.12, P=0.03). Importantly, β-blocker use before hospi-

Table 3. Logistic Regression Models for All-Cause Death				
Hazard ratio categories	All-cause death	U-BUN (reference)	D-BUN	I-BUN
No. of events (%)		25 (22.1)	38 (33.9)	57 (50.9)
No. of events/100 person-year		11.7	14.1	25.2
Unadjusted				
Hazard ratio		1.00	1.81	2.77
95% CI			1.00–3.27	1.73–4.44
P value	<0.001		0.049	<0.001
Baseline adjusted				
Hazard ratio		1.00	1.09	2.94
95% CI			0.54–2.21	1.51–5.73
P value	<0.001		0.81	0.002
Adjusted by the covariates including the change in clinical status				
Hazard ratio		1.00	0.93	4.26
95% CI			0.43–2.01	2.14–8.52
P value	<0.001		0.76	<0.001

See text for explanations of hazard ratio categories. Abbreviations as in Table 1.

A

BUN at hospitalization (1mg/dL per increase) — P value 0.17
BUN at discharge (1mg/dL per increase) — 0.01
BUN increase (group I-BUN) — <0.001
Cre level at hospitalization (1mg/dL per increase) — 0.015
Cre level at discharge (1mg/dL per increase) — 0.07
WRF during hospitalization — 0.41

Relative risk → Worse prognosis

B

BUN level at hospitalization >22.3mg/dL — P value 0.001
≤22.3mg/dL — 0.004 — P value for interaction 0.75
Cre level at hospitalization <0.96mg/dL — 0.009
≤0.96mg/dL — 0.002 — 0.79
(+) WRF during hospitalization — 0.47
(-) WRF during hospitalization — <0.001 — 0.35

Relative risk → Worse prognosis

Figure 3. Multivariable logistic analysis. (**A**) Models to compare the prognostic impact of BUN and creatinine levels at admission, BUN and creatinine levels at discharge and BUN increase and WRF during hospitalization for all-cause death. (**B**) Subgroup analysis of prognostic value of BUN increase according to serum BUN and creatinine levels at admission and WRF during hospitalization. BUN, blood urea nitrogen; WRF, worsening renal function.

Table 4. Predictors of BUN Increase During Hospitalization for AHFS

	Hazard ratio	95% CI	P value
Male (vs. female)	1.23	0.66–2.02	0.61
Age (per 1-year older)	1.01	0.99–1.04	0.34
Ischemic HF	1.02	0.56–1.86	0.96
Past history			
HF hospitalization	0.77	0.42–1.39	0.96
Diabetes	0.87	0.51–1.5	0.62
Malignant tumor	0.74	0.36–1.52	0.41
Cerebrovascular disease	0.87	0.45–1.67	0.67
Previous medications			
ACEIs	1.68	0.89–3.18	0.11
ARBs	0.85	0.45–1.6	0.62
Diuretics	1.19	0.66–2.15	0.56
β-blockers	0.51	0.26–0.99	0.047
Clinical condition at admission			
CS 1 (vs. CS 2 & 3)	1.81	1.05–3.12	0.03
HR (per 1 beat/min increase)	1	0.99–1.01	1
NYHA class III and IV (vs. class II)	1.81	0.19–16.9	0.6
SpO2 (per 1% decrease)	1.01	0.96–1.06	0.79
Hemoglobin (per 1 g/dl increase)	0.92	0.8–1.05	0.21
LVEF (per 1% increase)	1	0.98–1.01	0.56
eGFR (per 1 mml·min^{-1}·1.73m^{-2} increase)	0.99	0.7–1.42	0.97

AHFS, acute heart failure syndrome. Other abbreviations as in Tables 1,3.

talization was associated with 49% decrease in the incidence of the BUN increase during hospitalization (hazard ratio 0.51, 95% CI 0.26–0.99, P=0.047) (**Table 4**).

Discussion

The novel findings of the present study were that AHFS patients with increased BUN levels during hospitalization had worse long-term prognosis after discharge, regardless of renal function, and that the BUN increase during hospitalization was a strong predictor of the long-term prognosis of post-AHFS patients. Thus, the present study suggests that more attention should be paid to BUN changes during hospitalization for risk stratification of post-AHFS patients, regardless of creatinine-based measures of renal function.

Prognostic Importance of BUN Increase During AHFS Hospitalization

Elevated BUN level at admission is well known to be associated with increased in-hospital mortality and adverse outcomes after discharge.[2,4–8] However, the BUN level during hospitalization for AHFS often fluctuates dynamically because it is widely influenced not only by neurohumoral factors but also by several biological parameters, including fluid volume balance, nutritional status, and hemodynamics.[15] Therefore, it is clinically important to evaluate BUN changes during hospitalization to predict the prognosis of AHFS patients. In the present study, we found that the patients with increased BUN levels during hospitalization (I-BUN group) had the worse prognosis compared with those with unchanged BUN levels (U-BUN group) or decreased BUN levels (D-BUN group). Singh et al reported that BUN level at admission was more important than subsequent in-hospital fluctuations of BUN in terms of predicting short-term and long-term risk.[16] However, the length of the hospital stay in their study was shorter than in ours (5.3±6.4 vs. 30.4±19.4 days), which could explain the discrepancy in the results of the 2 studies.

We did not have enough data to examine the association between BUN increase and neurohumoral factors (eg, RAS activities). However, it has been reported that a higher BUN level is associated with a greater degree of elevation of neurohumoral activation.[17] Therefore, in the present study a BUN increase during AHFS hospitalization may have reflected activated neurohumoral systems.

Our results also demonstrated that the prognosis of the D-BUN group was relatively better than that of the I-BUN group, although the D-BUN group had worse clinical profiles characterized by higher prevalence of Nohria profile C, use of inotropes and lower eGFR at admission. Thus, it is suggested that even if AHFS patients have elevated BUN levels and a more severe clinical status at admission, their long-term prognosis could be improved if their BUN levels are decreased during hospitalization with intensive medical treatment.

WRF and BUN Increase During Hospitalization

It has been reported that WRF is a complication in approximately one-third of AHFS patients and is associated with poor prognosis.[11–14,18] In the present study, the I-BUN group had a higher prevalence of WRF, suggesting a close association between WRF and BUN increase during hospitalization. However, it is noteworthy that the effect of BUN increase during hospitalization (ie, I-BUN group) was associated with the worst long-term survival, regardless of the presence or absence of WRF. Indeed, the present study showed that an increase in BUN level had a higher hazard ratio in patients

without WRF than in those with WRF (**Figure 3B**). Thus, evaluation of BUN increase during hospitalization, regardless of WRF, could be important for appropriate risk stratification of AHFS patients.

Predictors for BUN Increase During AHFS Hospitalization

The present results showed that higher SBP at admission was significantly associated with BUN increase during hospitalization. In previous reports, higher SBP at admission was found to be a risk factor for WRF,[14] but AHFS patients with higher SBP, who were often classified as CS1, have significantly decreased mortality compared with those with normal or lower SBP.[19] Thus, caution should be paid to AHFS patients with higher SBP at admission, because they are likely to develop BUN increase during subsequent hospitalization, which may increase the risk of death after discharge. In the present study, SBP at 24–72 h after admission was almost same level among the 3 groups. However, the change in SBP during the 24–72 h after admission was –43.9±35.8 vs. –29.4±31.2 mmHg in the patients with WRF and those without WRF, respectively (P=0.03). Considering that early SBP drop may cause WRF in AHFS patients,[20] reduction in SBP should be achieved carefully in AHFS patients with higher SBP in order to prevent WRF and BUN increase during hospitalization.

AHFS Treatment to Prevent BUN Increase

In the present study, β-blockers use before admission was inversely associated with BUN increase during hospitalization (eg, 49% decrease in the I-BUN group). However, de novo AHFS accounted for approximately 70% of AHFS patients and only 24.6% patients had been treated with β-blocker(s) before admission. Considering the renal protective effects of β-blockers[21] their use before hospitalization for AHFS may be important to prevent BUN increase during hospitalization. Indeed, the ACC/AHA Guidelines recommend that β-blocker therapy should be started at the earlier stage of cardiovascular disease.[22] Thus, the present results may support the notion that β-blocker initiation at the earlier stage of HF could reduce the incidence of BUN increase through inhibition of SNS and RAS activation.

Study Limitations

Several limitations should be mentioned. First, this study was a retrospective observational study in Japan, so caution is needed when interpreting the present results in comparison with other cohorts. For example, the median hospital stay for AHFS in the present study (24.0 days) was much longer than in Western countries.[23,24] However, the present study suggests the importance of re-evaluating the BUN level, at a 1-month interval, for risk stratification of the patients. Second, the BUN measurement was not performed at a central laboratory. Third, the lack of assessment of pulmonary congestion or volume overload during hospitalization was a major limitation. Fourth, we did not have enough data on nutrition status (eg, serum albumin and body mass index), which may affect the BUN changes during hospitalization. However, we performed logistic analysis adjusted for fasting period, which may influence nutritional status, and found no influence of fasting. Finally, we excluded the patients who died during hospitalization, which might have influenced the present results.

Conclusions

AHFS patients with increased BUN levels during hospitalization have worse long-term prognosis after discharge, regard-

less of creatinine-based measures of renal function. Although it has been established that a higher BUN level at admission is associated with poor in-hospital prognosis, the present study provides further insights into the importance of BUN changes during hospitalization for risk stratification of AHFS patients.

Disclosures

Conflict of Interest: None.

References

1. Kazory A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. *Am J Cardiol* 2010; **106:** 694–700.
2. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: Classification and regression tree analysis. *JAMA* 2005; **293:** 572–580.
3. Chen CY, Yoshida A, Asakura M, Hasegawa T, Takahama H, Amaki M, et al. Serum blood urea nitrogen and plasma brain natriuretic peptide and low diastolic blood pressure predict cardiovascular morbidity and mortality following discharge in acute decompensated heart failure patients. *Circ J* 2012; **76:** 2372–2379.
4. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. *Am J Med* 2004; **116:** 466–473.
5. Smith GL, Shlipak MG, Havranek EP, Foody JM, Masoudi FA, Rathore SS, et al. Serum urea nitrogen, creatinine, and estimators of renal function: Mortality in older patients with cardiovascular disease. *Arch Intern Med* 2006; **166:** 1134–1142.
6. Kinugasa Y, Kato M, Sugihara S, Hirai M, Kotani K, Ishida K, et al. A simple risk score to predict in-hospital death of elderly patients with acute decompensated heart failure: Hypoalbuminemia as an additional prognostic factor. *Circ J* 2009; **73:** 2276–2281.
7. Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: Insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. *J Card Fail* 2007; **13:** 360–364.
8. Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams KF Jr, et al; OPTIME-CHF Investigators. Hospitalization or changes in renal function during hospitalization for worsening heart failure predict post discharge survival: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). *Circ Heart Fail* 2008; **1:** 25–33.
9. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. *N Engl J Med* 1971; **285:** 1441–1446.
10. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Esti-
mation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. *Clin Exp Nephrol* 2007; **11:** 41–50.
11. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, et al. Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. *Am J Cardiol* 2000; **85:** 1110–1113.
12. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, et al. Incidence, predictors at hospitalization, and impact of worsening renal function among patients hospitalized with heart failure. *J Am Coll Cardiol* 2004; **43:** 61–67.
13. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: Results of the prospective outcomes study in heart failure (POSH). *Eur Heart J* 2006; **27:** 1216–1222.
14. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. *J Card Fail* 2010; **16:** 541–547.
15. Gotsman I, Zwas D, Planer D, Admon D, Lotan C, Keren A. The significance of serum urea and renal function in patients with heart failure. *Medicine (Baltimore)* 2010; **89:** 197–203.
16. Singh G, Peterson EL, Wells K, Williams LK, Lanfear DE. Comparison of renal predictors for in-hospital and postdischarge mortality after hospitalized heart failure. *J Cardiovasc Med* 2012; **13:** 246–253.
17. Schrier RW. Blood urea nitrogen and serum creatinine: Not married in heart failure. *Circ Heart Fail* 2008; **1:** 2–5.
18. Shirakabe A, Hata N, Kobayashi N, Shinada T, Tomita K, Tsurumi M, et al. Prognostic impact of acute kidney injury in patients with acute decompensated heart failure. *Circ J* 2013; **77:** 687–696.
19. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al; OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at hospitalization, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. *JAMA* 2006; **296:** 2217–2226.
20. Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, et al; Pre-RELAX-AHF study group. Early drop in systolic blood pressure and worsening renal function in acute heart failure: Renal results of Pre-RELAX-AHF. *Eur J Heart Fail* 2011; **13:** 961–967.
21. Ito H, Nagatomo Y, Kohno T, Anzai T, Meguro T, Ogawa S, et al. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. *Circ J* 2010; **74:** 1578–1583.
22. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the ACC/AHA Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. *J Am Coll Cardiol* 2009; **53:** e1–e90.
23. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J* 2005; **149:** 209–216.
24. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. *Eur Heart J* 2006; **27:** 2725–2736.